Glial-derived neurotrophic factor gene transfer for Parkinson's disease: Anterograde distribution of AAV2 vectors in the primate brain

Neurobiology of Disease

Volumn 48, Issue 2, 2012, Pages 228-235

  Kells, Adrian P ^a   Forsayeth, John ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno associated viral vectors; Anterograde transport; Drug delivery; Gene therapy; Glial derived neurotrophic factor; Parkinson's disease

Indexed keywords

ADENO ASSOCIATED VIRUS 2 VECTOR; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

BRAIN DAMAGE; BRAIN LEVEL; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG TRANSPORT; GENE; GENE EXPRESSION; GENE LOCATION; GENE TARGETING; GENE TRANSFER; GLIAL DERIVED NEUROTROPHIC FACTOR GENE; HUMAN; HYPOTHALAMUS; IMAGING SYSTEM; MESENCEPHALON; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; PUTAMEN; REVIEW; SUBSTANTIA NIGRA; SYMPTOM; TREATMENT RESPONSE; VENTRAL TEGMENTUM; VIRAL GENE DELIVERY SYSTEM; WEIGHT REDUCTION;

ANIMALS; BRAIN; BRAIN CHEMISTRY; DEPENDOVIRUS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; PARKINSON DISEASE; PRIMATES;

EID: 84865556534     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.10.004     Document Type: Review

References (48)

1. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3(5):383-394.
2. Bartus R.T., Herzog C.D., Chu Y., Wilson A., Brown L., Siffert J., Johnson E.M., Olanow C.W., Mufson E.J., Kordower J.H. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 2011, 26(1):27-36.
3. Cattaneo A., Capsoni S., Paoletti F. Towards non invasive nerve growth factor therapies for Alzheimer's disease. J. Alzheimers Dis. 2008, 15(2):255-283.
4. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275(5301):838-841.
5. Choi-Lundberg D.L., Lin Q., Schallert T., Crippens D., Davidson B.L., Chang Y.N., Chiang Y.L., Qian J., Bardwaj L., Bohn M.C. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 1998, 154(2):261-275.
6. Christine C.W., Starr P.A., Larson P.S., Eberling J.L., Jagust W.J., Hawkins R.A., VanBrocklin H.F., Wright J.F., Bankiewicz K.S., Aminoff M.J. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73(20):1662-1669.
7. Ciesielska A., Mittermeyer G., Hadaczek P., Kells A.P., Forsayeth J., Bankiewicz K.S. Anterograde Axonal Transport of AAV2-GDNF in Rat Basal Ganglia. Mol. Ther. 2011, 19(5):922-927.
8. Connor B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 1999, 6(12):1936-1951.
9. Eberling J.L., Bankiewicz K.S., O'Neil J.P., Jagust W.J. PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates. Front. Hum. Neurosci. 2007, 1:9.
10. Eslamboli A., Cummings R.M., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Kirik D., Annett L.E. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 2003, 184(1):536-548.
11. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380(6571):252-255.
12. Granholm A.C., Reyland M., Albeck D., Sanders L., Gerhardt G., Hoernig G., Shen L., Westphal H., Hoffer B. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J. Neurosci. 2000, 20(9):3182-3190.
13. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elsberry D.D., Klein M.C., Gerhardt G.A., Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002, 125(Pt 10):2191-2201.
14. Hadaczek P., Kohutnicka M., Krauze M.T., Bringas J., Pivirotto P., Cunningham J., Bankiewicz K. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 2006, 17(3):291-302.
15. Hovland D.N., Boyd R.B., Butt M.T., Engelhardt J.A., Moxness M.S., Ma M.H., Emery M.G., Ernst N.B., Reed R.P., Zeller J.R., Gash D.M., Masterman D.M., Potter B.M., Cosenza M.E., Lightfoot R.M. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol. Pathol. 2007, 35(5):676-692.
16. Johnston L.C., Eberling J., Pivirotto P., Hadaczek P., Federoff H.J., Forsayeth J., Bankiewicz K.S. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum. Gene Ther. 2009, 20(5):497-510.
17. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., During M.J. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369(9579):2097-2105.
18. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 1995, 672(1-2):104-111.
19. Kells A.P., Eberling J., Su X., Pivirotto P., Bringas J., Hadaczek P., Narrow W.C., Bowers W.J., Federoff H.J., Forsayeth J., Bankiewicz K.S. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J. Neurosci. 2010, 30(28):9567-9577.
20. Kells A.P., Hadaczek P., Yin D., Bringas J., Varenika V., Forsayeth J., Bankiewicz K.S. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(7):2407-2411.
21. Kirik D., Georgievska B., Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 2004, 7(2):105-110.
22. Kirik D., Georgievska B., Rosenblad C., Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci. 2001, 13(8):1589-1599.
23. Kirik D., Rosenblad C., Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 2000, 12(11):3871-3882.
24. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 2000, 20(12):4686-4700.
25. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290(5492):767-773.
26. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., Mufson E.J., Penn R., Goetz C.G., Comella C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 1999, 46(3):419-424.
27. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59(3):459-466.
28. LeWitt P.A., Rezai A.R., Leehey M.A., Ojemann S.G., Flaherty A.W., Eskandar E.N., Kostyk S.K., Thomas K., Sarkar A., Siddiqui M.S., Tatter S.B., Schwalb J.M., Poston K.L., Henderson J.M., Kurlan R.M., Richard I.H., Van Meter L., Sapan C.V., During M.J., Kaplitt M.G., Feigin A. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011, 10(4):309-319.
29. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260(5111):1130-1132.
30. Manfredsson F.P., Burger C., Rising A.C., Zuobi-Hasona K., Sullivan L.F., Lewin A.S., Huang J., Piercefield E., Muzyczka N., Mandel R.J. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol. Ther. 2009, 17(11):1857-1867.
31. Manfredsson F.P., Tumer N., Erdos B., Landa T., Broxson C.S., Sullivan L.F., Rising A.C., Foust K.D., Zhang Y., Muzyczka N., Gorbatyuk O.S., Scarpace P.J., Mandel R.J. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol. Ther. 2009, 17(6):980-991.
32. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., Vitek J., Stacy M., Turner D., Verhagen L., Bakay R., Watts R., Guthrie B., Jankovic J., Simpson R., Tagliati M., Alterman R., Stern M., Baltuch G., Starr P.A., Larson P.S., Ostrem J.L., Nutt J., Kieburtz K., Kordower J.H., Olanow C.W. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9(12):1164-1172.
33. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7(5):400-408.
34. Muramatsu S., Fujimoto K., Kato S., Mizukami H., Asari S., Ikeguchi K., Kawakami T., Urabe M., Kume A., Sato T., Watanabe E., Ozawa K., Nakano I. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 2010, 18(9):1731-1735.
35. Muramatsu S.-i., Fujimoto K.-i., Kato S., Asari S., Mizukami H., Ikeguchi K., Kawakami T., Urabe M., Kume A., Sato T., Watanabe E., Ozawa K., Nakano I. Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease: Results from an Open-Label, Phase I Trial 2009, American Society for Gene Therapy, San Diego, CA, USA.
36. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., Lozano A.M., Penn R.D., Simpson R.K., Stacy M., Wooten G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60(1):69-73.
37. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 2008, 11(7):755-761.
38. Patel N.K., Gill S.S. GDNF delivery for Parkinson's disease. Acta Neurochir. Suppl. 2007, 97(Pt 2):135-154.
39. Richardson R.M., Kells A.P., Martin A.J., Larson P.S., Starr P.A., Piferi P.G., Bates G., Tansey L., Rosenbluth K.H., Bringas J.R., Berger M.S., Bankiewicz K.S. Novel Platform for MRI-Guided Convection-Enhanced Delivery of Therapeutics: Preclinical Validation in Nonhuman Primate Brain. Stereotact. Funct. Neurosurg. 2011, 89(3):141-151.
40. Richardson R.M., Kells A.P., Rosenbluth K.H., Salegio E.A., Fiandaca M.S., Larson P.S., Starr P.A., Martin A.J., Lonser R.R., Federoff H.J., Forsayeth J.R., Bankiewicz K.S. Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease. Mol. Ther. 2011, 19(6):1048-1057.
41. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. Neurol. 1993, 124(2):401-412.
42. Su X., Kells A.P., Aguilar Salegio E.A., Richardson R.M., Hadaczek P., Beyer J., Bringas J., Pivirotto P., Forsayeth J., Bankiewicz K.S. Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol. Ther. 2010, 18(8):1490-1495.
43. Su X., Kells A.P., Huang E.J., Lee H.S., Hadaczek P., Beyer J., Bringas J., Pivirotto P., Penticuff J., Eberling J., Federoff H.J., Forsayeth J., Bankiewicz K.S. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum. Gene Ther. 2009, 20(12):1627-1640.
44. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373(6512):335-339.
45. Tomac A., Widenfalk J., Lin L.F., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(18):8274-8278.
46. Valles F., Fiandaca M.S., Eberling J.L., Starr P.A., Larson P.S., Christine C.W., Forsayeth J., Richardson R.M., Su X., Aminoff M.J., Bankiewicz K.S. Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery 2010, 67(5):1377-1385.
47. Yin D., Richardson R.M., Fiandaca M.S., Bringas J., Forsayeth J., Berger M.S., Bankiewicz K.S. Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J. Neurosurg. 2010, 113(2):240-248.
48. Yin D., Valles F.E., Fiandaca M.S., Bringas J., Gimenez F., Berger M.S., Forsayeth J., Bankiewicz K.S. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 2011, 54(Suppl 1):S196-203.